News & Topics
News&Topics

2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2016.12.19
Analyst Report: Shared Research updates the report
2016.12.19
Approval in Japan of the Anti-cancer Drug TREAKISYM® for the Additional Indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
2016.12.06
Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting
2016.11.22
Initiation of Patient Enrollment in the Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
2016.11.14
Notice of Shareholder Voting Results for the Extraordinary Shareholders' Meeting
2016.11.11
Analyst Report: Shared Research updates the report
2016.11.11
Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.11.11
Notice concerning Non-operating Expenses
2016.10.20
Information on The Extraordinary Shareholders' Meeting: Updated the Page
2016.10.03
Notice concerning the Change in Major and Largest Shareholder among the Company's Major Stockholders
2016.09.28
Approval in Japan of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg
2016.09.27
Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes
2016.09.15
Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
2016.09.15
Notice concerning Partial Amendment to the Articles of Incorporation
2016.09.12
Analyst Report: Shared Research updates the report
2016.08.26
Approval of the Anti-cancer Drug TREAKISYM® for the Additional Indication of Chronic Lymphocytic Leukemia
2016.08.04
Analyst Report: Shared Research updates the report
2016.08.04
Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.08.04
Notice Concerning Non-operating Expenses
2016.07.19
Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3 Trial of IV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS)
2016.06.16
Corporate governance policies
2016.06.14
Onconova Announces Presentation of Clinical Data from Oral Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting
2016.06.13
Analyst Report: Shared Research updates the report
2016.06.13
Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
2016.06.08
Notice concerning the Change of Major Shareholder
2016.06.07
Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting
2016.06.02
Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting
2016.05.30
Notice concerning the Change of Major Shareholder
2016.05.24
Notice concerning the Change of Major Shareholder
2016.05.20
Notice concerning Cancellation of the Extraordinary Shareholders' Meeting on July 15, 2016 and Cancellation of the Record Date therefor
2016.05.19
Notice concerning the Change of Major and Largest Shareholder among the Company's Major Stockholders
2016.05.11
SymBio Announces Incorporation of its U.S. Subsidiary
2016.05.10
Analyst Report: Shared Research updates the report
2016.05.10
Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
2016.05.10
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.05.10
Notice Concerning Non-operating Expenses
2016.04.22
Completion of Payment for Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
2016.04.14
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2016.04.14
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2016.04.06
Analyst Report: Shared Research updates the report
2016.04.06
Notice of the Issuance of and the Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
2016.03.31
(Correction) Notice concerning partial correction to the "Notice of Appointment of Directors"
2016.03.31
Notice of Shareholder Voting Results for the 11th Ordinary General Meeting of Shareholders
2016.03.30
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
2016.03.30
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
2016.03.30
Notice of Appointment of Directors
2016.03.23
Analyst Report: Edison updates the report
2016.03.21
Analyst Report: Edison updates the report
2016.03.17
Analyst Report: Shared Research updates the report
2016.03.11
Information on Shareholders' Meeting: Updated the Page
2016.03.10
Notice concerning Partial Amendment to the Articles of Incorporation and Nomination of Director Candidates
2016.03.10
Onconova Announces Publication of Results from the ONTIME Trial for rigosertib in MDS
2016.02.10
Analyst Report: Shared Research updates the report
2016.02.10
SymBio's Long Range Plan: FY2016 to FY2018
2016.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2015[Japanese GAAP] (Non-consolidated)
2016.02.10
Notice Concerning Non-operating Expenses
2016.02.08
SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
2016.02.04
Assessment Status of Bendamustine in Europe